This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Metformin dose in polycystic ovary syndrome (PCOS)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

A study examined different dose regimes in polycystic ovary syndrome (PCOS):

  • A :500 mg twice a day (1000 mg);
  • B :500 mg three times a day (1500 mg);
  • C :850 mg twice a day (1700 mg).

The study study comprehensively analysed the dose-response relationship of metformin on clinical, hormonal and metabolic aspects of PCOS.

The authors concluded that "... results from our study seem to indicate that the effects of metformin treatment in PCOS are independent of the administered dose. Different anthropometrical and metabolic characteristics do not give grounds for an adjustment of the dose of the drug. Hence, since metformin efficacy in PCOS seems not to be dose related, while side effects are, low dosages should be preferred in the clinical practice."

Titration of metformin

An NHS source suggests a titration schedules for metformin (1) with women with side effects having a slower titration to a target dose of 1g twice daily of metformin.

Slow route (in women with side effects) as:

  • Week 1 - 250mg once a day
  • Week 2 - 250mg twice a day
  • Week 3 - 250mg three times a day
  • Week 4 - 500mg twice a day
  • Week 5 - 500mg three times a day
  • Week 6 - 1g twice a day

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.